

# **Purified Human Pancreatic Islet: Qualitative and Quantitative Assessment of Islets Using Dithizone (DTZ) – *Standard Operating Procedure of the NIH Clinical Islet Transplantation Consortium***

## **The NIH CIT Consortium Chemistry Manufacturing Controls Monitoring Committee:**

J. Ansite, A.N. Balamurugan, B. Barbaro, J. Battle, D. Brandhorst, J. Cano, X. Chen, S. Deng, D. Feddersen, A. Friberg, T. Gilmore, J.S. Goldstein, E. Holbrook, A. Khan, T. Kin, J. Lei, E. Linetsky, C. Liu, X. Luo, K. McElvaney, Z. Min, J. Moreno, D. O’Gorman, K.K. Papas, G. Putz, C. Ricordi, G. Szot, T. Templeton, L. Wang, J.J. Wilhelm, J. Willits, T. Wilson, X. Zhang

## **The NIH CIT Consortium**

**Emory University:** J. Avila, B. Begley, J. Cano, S. Carpentier, E. Holbrook, J. Hutchinson, C.P. Larsen, J. Moreno, M. Sears, N.A. Turgeon, D. Webster

**Massachusetts General Hospital:** S. Deng, J. Lei, J.F. Markmann

**NIAID:** N.D. Bridges, C.W. Czarniecki, J.S. Goldstein, G. Putz, T. Templeton, T. Wilson

**NIDDK:** T.L. Eggerman

**Northwestern University:** P. Al-saden, J. Battle, X. Chen, A. Hecyk, H. Kissler, X. Luo, M. Molitch, N. Monson, E. Stuart, A. Wallia, L. Wang, S. Wang, X. Zhang

**University of Alberta, Edmonton:** D. Bigam, P. Campbell, P. Dinyari, T. Kin, N. Kneteman, J. Lyon, A. Malcolm, D. O’Gorman, C. Onderka, R. Owen, R. Pawlick, B. Richer, S. Rosichuk, D. Sarman, A. Schroeder, P.A. Senior, A.M.J. Shapiro, L. Toth, V. Toth, W. Zhai

**University of California–San Francisco:** K. Johnson, J. McElroy, A.M. Posselt, M. Ramos, T. Rojas, P.G. Stock, G. Szot

**University of Illinois, Chicago:** B. Barbaro, J. Martellotto, J. Oberholzer, M. Qi, Y. Wang

**University of Iowa (Data Coordinating Center):** L. Bayman, K. Chaloner, W. Clarke, J.S. Dillon, C. Diltz, G.C. Doelle, D. Ecklund, D. Feddersen, E. Foster, L. G. Hunsicker, C. Jaspersen, D-E Lafontant, K. McElvaney, T. Neill-Hudson, D. Nollen, J. Qidwai, H. Riss, T. Schwieger, J. Willits, J. Yankey

**University of Miami:** R. Alejandro, A.C. Corrales, R. Faradji, T. Froud, A.A. Garcia, E. Herrada, H. Ichii, L. Inverardi, N. Kenyon, A. Khan, E. Linetsky, J. Montelongo, E. Peixoto, K. Peterson, C. Ricordi, J. Szust, X. Wang

**University of Minnesota:** M.H. Abdulla, J. Ansite, A.N. Balamurugan, M.D. Bellin, M. Brandenburg, T. Gilmore, J. V. Harmon, B.J. Hering, R. Kandaswamy, G. Loganathan, K. Mueller, K.K. Papas, J. Pedersen, J.J. Wilhelm, J. Witson

**University of Pennsylvania:** C. Dalton-Bakes, H. Fu, M. Kamoun, J. Kearns, Y. Li, C. Liu, E. Luning-Prak, Y. Luo, E. Markmann, Z. Min, A. Najj, M. Palanjian, M. Rickels, R. Shlansky-Goldberg, K. Vivek, A.S. Ziaie

**University of Wisconsin:** L. Fernandez, D.B. Kaufman, L. Zitur

**Uppsala University:** D. Brandhorst, A. Friberg, O. Korsgren

*Supported by grants from the National Institute of Allergy and Infectious Diseases and the National Institute for Diabetes and Digestive and Kidney Diseases.*

- At Emory University, U01AI089317.
- At Northwestern University, U01AI089316.
- At the University of Alberta, Edmonton: U01AI065191.
- At the University of California, San Francisco, U01DK085531.
- At the University of Illinois, Chicago, 5U01DK070431-10.
- At the University of Iowa, U01DK070431.
- At the University of Miami, U01DK070460.
- At the University of Minnesota, U01AI065193.
- At the University of Pennsylvania, U01DK070430.
- At Uppsala University, U01AI065192.

*In addition, the study was supported by the following GCRC and CTSA awards:*

- At Emory University: UL1TR000454.
- At Northwestern University: 5UL1RR025741 and 8UL1TR000150.
- At the University of California, San Francisco, UL1TR000004.
- At the University of Illinois, Chicago, UL1TR000050.
- At the University of Miami: 1UL1TR000460.
- At the University of Minnesota: 5M01-RR000400 and UL1TR000114.
- At the University of Pennsylvania: UL1TR000003.

Address correspondence to: Camillo Ricordi MD, Chairman, CIT Steering Committee, ricordi@miami.edu

**To cite this article**

*Purified Human Pancreatic Islet: Qualitative and Quantitative Assessment of Islets Using Dithizone (DTZ) – Standard Operating Procedure of the NIH Clinical Islet Transplantation Consortium*

CellR4 2015; 3 (1): e1369



<b>Document No.</b> 3104, A01	<b>Revision Number</b> 00	<b>Effective Date</b> 07 July 2008	<b>Supersedes Date</b> N/A	<b>Page 1 of 5</b>
----------------------------------	------------------------------	---------------------------------------	-------------------------------	--------------------

**Document Title:**

**PURIFIED HUMAN PANCREATIC ISLETS,  
QUALITATIVE & QUANTITATIVE ASSESSMENT OF ISLETS USING DITHIZONE  
(DTZ)**

**PURPOSE:** To be a model for site-specific SOPs that define the assay method for quantitative and qualitative determination of the Purified Human Pancreatic Islet product manufactured for use in the DAIT-sponsored clinical studies in the CIT consortium.

**RESPONSIBILITY:** It is the responsibility of the Islet Cell Processing Principal Investigator or designee to:

- establish a site-specific SOP based on this document,
- train the site personnel in the execution of the site-specific procedure,
- validate the site-specific procedure,
- assure that the site-specific procedure is executed, and
- maintain records of the execution of the site-specific procedure.

**SCOPE:** This SOP applies to trained personnel participating in the CIT consortium manufacturing the Purified Human Pancreatic Islets product for use in DAIT-sponsored clinical studies.

**I. INTRODUCTION**

Dithizone (diphenyl thiocarbazone, DTZ) is an organic chemical that chelates the zinc in the insulin granules present in the beta cells of the pancreatic islets. The islet cells are stained red while the acinar cells remain unstained.

DTZ staining is used as a lot release and as an in-process assay:

- (i) Lot release testing: DTZ staining is used to identify islets and to determine the quantity and quality of the final islet product. Islet quantity is expressed as the number of islet equivalents (IEQ), which is calculated based on the number and diameter of the islets present in the preparation, mathematically corrected for islet volume.
- (ii) In-process testing: DTZ staining is used to identify islets and to assess the effectiveness of the digestion, isolation and purification processes. The quality of the preparations is expressed as percent islet purity, and percent trapped islets. Islet quantity (IEQ) is also assessed.

**II. DEFINITIONS**

- A. Percent Purity:** the percentage of islets compared to all tissue present in the islet preparation (islets, acinar and ductal cells), determined by visual inspection of a representative sample of the islet preparation.
- B. Percent Trapped:** the percentage of islets that are embedded or trapped in acinar tissue (at least 25% of the border attached to acinar tissue) compared to all islets (free and trapped), determined by visual inspection of a representative sample of the islet preparation.

<b>Document No.</b> 3104, A01	<b>Revision Number</b> 00	<b>Effective Date</b> 07 July 2008	<b>Supersedes Date</b> N/A	<b>Page 2 of 5</b>
<b>Document Title:</b>				
<b>PURIFIED HUMAN PANCREATIC ISLETS, QUALITATIVE &amp; QUANTITATIVE ASSESSMENT OF ISLETS USING DITHIZONE (DTZ)</b>				

- C. Islet Particle Number (IPN):** The number of islets counted.
- D. Islet Equivalent (IEQ):** an islet that is 150  $\mu\text{m}$  in diameter. Islets of varying diameters are normalized to a number of Islet Equivalents of 150  $\mu\text{m}$  diameter by mathematically compensating for their volumes.
- E. Equations for Total Islet Equivalent (Total IEQ) and Total Islet Particle Number (Total IPN):**
1. Total IEQ = Dilution Factor X  
 [(IPN of diameter 50 – 100  $\mu\text{m}$  X 0.167) +  
 (IPN of diameter 101 – 150  $\mu\text{m}$  X 0.667) +  
 (IPN of diameter 151 – 200  $\mu\text{m}$  X 1.685) +  
 (IPN of diameter 201 – 250  $\mu\text{m}$  X 3.500) +  
 (IPN of diameter 251 – 300  $\mu\text{m}$  X 6.315) +  
 (IPN of diameter 301 – 350  $\mu\text{m}$  X 10.352) +  
 (IPN of diameter > 350  $\mu\text{m}$  X 15.833)]
  2. Total IPN = Dilution Factor X  $\sum$  IPN of each diameter

### III. MATERIALS

- A. Equipment**
- Light Microscope
  - Eyepiece with calibrated reticle, 1 mm
  - Computer with Excel Counting Worksheet or equivalent
  - Manual or Electronic Cell Counter
- B. Supplies and Materials**
- Positive displacement pipette and associated tips
  - 0.45  $\mu\text{m}$  nylon filter
  - Sterile 10 x 35 mm counting dishes with grid marks
  - Dithizone (DTZ) (Sigma Cat. #D5130)
  - Dulbecco's Phosphate Buffered Saline (DPBS), Mediatech Part #99-597 or equivalent
  - Dimethyl sulfoxide, DMSO (Sigma Cat. #D8779 or equivalent)
- C. Attachment**
- "Islet Counting Worksheet"

### IV. PROCEDURE

- A. Assay set up**
- Assemble all items described in the Section III, "Materials."
  - Prepare DTZ stain as described below.

<b>Document No.</b> 3104, A01	<b>Revision Number</b> 00	<b>Effective Date</b> 07 July 2008	<b>Supersedes Date</b> N/A	<b>Page 3 of 5</b>
<b>Document Title:</b>				
<b>PURIFIED HUMAN PANCREATIC ISLETS, QUALITATIVE &amp; QUANTITATIVE ASSESSMENT OF ISLETS USING DITHIZONE (DTZ)</b>				

**DTZ Solution Preparation**

- a. Dissolve: 50 mg dithizone in 10 mL DMSO.
- b. qs to 50 mL with DPBS.
- c. Filter the combined solution using a 0.45 µm nylon filter.
- d. Place solution in a 50 mL conical tube and label it
  - “Dithizone Stain”
  - Preparation Date and Time
  - Expiration Date and Time (24 hours after preparation)
  - Initials of person preparing solution

**B. Islet Cell Quantitation**

1. Mix the final islets suspension very gently but thoroughly before taking a sample. As islets settle rapidly, care must be taken to ensure a representative sample is taken.
2. Take sample volumes and replicates according to the Table, below. Place each sample in a 10 x 35 mm counting dish with grid lines.

**Table: Sampling and replicates for islets evaluation by DTZ**

	<b>Sample</b>	<b>No. of replicates, Sample Volume</b>	<b>Assay</b>
<b>In-Process or Intermediate Islet Product</b>	Digest	Multiple, 1-2 mL from digest	Identity, Digest Progress
	Pre-purification	Duplicate, 100 µL from 200 g	Identity, Count
	Continuous Purification Fractions	Single, 500 µL from 250 mL	Identity, % Purity
	Discontinuous Purification Fractions	500 µL, of each fraction	Identity, % Purity
	Post-purification	Duplicate, 100 µL from 100 g	Identity, Count
<b>Final Product</b>		Duplicate, 100 µL from 100 mL	Identity, Count

3. Add 3 drops (30 µL) of the DTZ solution to the islets sample and allow staining for 1 – 2 minutes at room temperature. Cover the bottom of the counting dish with DPBS to approximately 1/2 the height of the dish. Count the islets under the microscope following the steps below.
4. Examine the islets sample (stained islets will appear red) using the 10X eyepiece and the 4X objective to give a total magnification of 40X. Using the grid lines on the counting dish as a guide, methodically scroll through the dish from side to side, and top to bottom, examining each islet. Count islets within the perimeter of the grid’s squares, including only islets touching the top and right lines (not the bottom and left lines), to avoid counting the same islet twice.
5. Use a reticle certified to a correction factor of 0.98 to 1.02 in the eyepiece of the light microscope to determine the size of each islet. The distance across two spaces on the calibrated reticle in the eyepiece equals 50 µm. Do not count islets smaller than 50 µm because their contribution is not significant. Using the table below as a guide, place each islet into one of the diameter groups.

Number of Spaces Spanned	Diameter of Islet (µm)
< 2	< 50
2 – 4	50 – 100
4 – 6	101 – 150
6 – 8	151 – 200
8 – 10	201 – 250
10 – 12	251 – 300
12 – 14	301 – 350
> 14	> 350

6. Count the number of islets in each diameter group using the manual or electronic cell counter. If there is a print-out, attach it to the Production Batch Record.
7. Calculate the dilution factor as follows:  
  

$$\frac{\text{Total volume of preparation that sample taken from (mL)} \times (1000)}{\text{Volume of sample taken (µL)}} = \text{Dilution Factor}$$
8. Calculate the Total Islet Particle Number (Total IPN), and the Total Islet Equivalents (Total IEQ) using the formulas provided in Section II, E, above, and record the results in the Table in the Production Batch Record.

Example for a 100 µL sample from a 100 mL total volume:

Islet Diameter Range (µm)	Islet Particle Number (IPN)	IEQ Conversion Factor	IEQ per Range
50 – 100	11	X 0.167	1.837
101 – 150	42	X 0.648	27.216
151 – 200	26	X 1.685	43.810
201 – 250	13	X 3.500	45.500
251 – 300	5	X 6.315	31.575
301 – 350	0	X 10.352	0
> 350	1	X 15.833	15.833
<b>Σ IPN</b>	<b>98</b>	<b>Σ IEQ</b>	<b>165.771</b>
Dilution Factor [(mL total volume / µL sample volume) X 1000]			1000
Total IPN = Σ IPN X Dilution Factor			98,000
Total IEQ = Σ IEQ X Dilution Factor			165,771

<b>Document No.</b> 3104, A01	<b>Revision Number</b> 00	<b>Effective Date</b> 07 July 2008	<b>Supersedes Date</b> N/A	<b>Page 5 of 5</b>
<b>Document Title:</b>				
<b>PURIFIED HUMAN PANCREATIC ISLETS, QUALITATIVE &amp; QUANTITATIVE ASSESSMENT OF ISLETS USING DITHIZONE (DTZ)</b>				

**C. Percent Free Islets & Percent Trapped Islets Determination**

1. Methodically examine at least 50 islets to determine if each is free or trapped. Free islets have less than 25% of their border attached to acinar tissue. Trapped islets have 25% or more of their border attached to acinar tissue.
2. Record these quantities in the Table in the Production Batch Record.
3. Calculate to 1% the percent free and the percent trapped by dividing the number free islets and the number trapped islets, respectively, by total number of islets counted.

Example:

# of free islets	32	÷ total # of islets X 100	54	= % free islets	59%
# of trapped islets	22	÷ total # of islets X 100	54	= % trapped islets	41%

4. Record the results in the Table in the Production Batch Record.

**D. Percent Purity**

1. Determine the percent purity to the nearest 5% by estimating the proportion of red-stained islets to all the tissue (islets, acinar, ductal cells) across several fields.
2. Record the result in the Table in the Production Batch Record.

**V. RECORD REVIEW**

Records will be reviewed as defined by the site-specific SOPs. At a minimum the operator supervisor and/or QA personnel should review the records.

**VI. RECORD RETENTION**

Records will be maintained by the manufacturing facility following the time period specified in the site-specific SOP describing Record Retention and Record Archival System. Do not destroy any records without consulting previously with DAIT, NIAID, NIH.

**VII. REFERENCES**

Ricordi, C. Pancreatic Islet Cell Transplantation. Austin: R.G. Landes Company, 1992:137-138.

Ricordi, C. (Ed). Methods in Cell Transplantation. Austin: R.G. Landes Company, 1995:Section G.